Estech, a San Ramon, Calif.-based developer and supplier of a minimally invasive cardiac ablation surgical platform, has completed a $8.5m equity financing.
Investors include Saints Capital Everest, Telegraph Hill Partners, NBGI Ventures and Tullis Health Investors. Over the last two years, Estech has raised over $28m.
The company intends to use the funds to further develop of platform.
Estech’s surgical cardiac ablation device is designed to be used endoscopically through three small ports on the right side of the chest. The procedure is typically performed in 60 to 90 minutes, and in some cases has been performed under epidural as opposed to general anesthesia.
It has been approved to treat atrial fibrillation in Europe under CE mark and has FDA 510(k) clearance for cardiac ablation in the U.S.